Evaluating Hidden Heart Disease in Men Who Survived Testicular Cancer Treated with Cisplatin Chemotherapy and Bone Marrow Transplant

What this Trial Is About

Researchers are studying late hidden heart disease in young adult males who survived testicular cancer and were treated with cisplatin-based chemotherapy and bone marrow transplant. This study focuses on detecting early signs of atherosclerotic cardiovascular disease ASCVD that can occur 10 or more years after treatment. It addresses the need for early detection since traditional screening often misses younger survivors under 40-45 years old. The study compares three groups of testicular cancer survivors those treated with surgery or surveillance only, those treated with cisplatin-based chemotherapy, and those treated with chemotherapy plus bone marrow transplant. Participants undergo advanced tests including blood lipid profiles, coronary artery CT scans, and hormone level checks for hypogonadism. These assessments occur more than 5 years after their cancer diagnosis. Participants are cancer-free at the time of evaluation and will be assessed once at recruitment. The study measures lipid profiles and coronary plaque presence through imaging, with secondary assessments of hormone levels and serum platinum. This observational study carefully monitors heart disease risk factors in survivors to better understand late cardiovascular effects after testicular cancer treatment.

Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors